Deals in Depth: April 2012
Forest paid Janssen $357 million to acquire US and Canadian IP related to Bystolic. Nestle bought Pfizer’s nutritional’s business and Hologic beefed up its women’s health portfolio through its $3.8 billion Gen-Probe takeover. Both biopharma and medical device financing were down in April compared with last month.
You may also be interested in...
Despite disappointment in its Phase III study, Roche is preparing a new trial of the antisense therapy in patients with a lower disease burden.
The German biotech inks its fifth metabolic disease collaboration as it teams up with US major Eli Lilly to develop kidney disease and diabetes assets.
Medicines for Ireland has appointed Accord Healthcare Ireland managing director Padraic O’Brien as chairperson and Teva Ireland director of generic products Paul Neill as vice chairperson of the Irish industry association. The changes come just a few weeks after Ireland implemented its new framework agreement on off-patent pricing.